Synchronized Transcranial Magnetic Stimulation for PTSD

Depression Clinical Trial

— sTMS  

Official title:

Synchronized TMS for Posttraumatic Stress Disorder and Comorbid Depressive Symptoms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02981381
• Other study ID #: 2016-004
• Secondary ID: 1010584-1
• Status: Completed
• Phase: Phase 2
• Start date: October 13, 2016
• Est. completion date: October 26, 2018

Study information

• Verified date: January 2019
• Source: Providence VA Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators propose a small, two-site, sham-controlled pilot study of synchronized Transcranial Magnetic Stimulation (sTMS) in patients with comorbid post-traumatic stress disorder (PTSD) and depression. It is hypothesized that sTMS will be effective for PTSD and mood symptoms.

Description:

Posttraumatic stress disorder (PTSD) is a highly prevalent psychiatric disorder associated with high degrees of comorbidity (e.g., major depressive disorder), poor quality of life, and significant social and occupational dysfunction. Currently available evidence-based pharmacological and psychological treatments for PTSD have only modest efficacy, and thus further research is necessary to develop treatment approaches in order to ameliorate the current disparity between disorder impact and prevalence, and effective therapies.

The use of non-invasive neuromodulation techniques, such as repetitive transcranial magnetic stimulation (rTMS), in an outpatient setting, has shown to be effective in reducing symptoms in various mental disorders, including PTSD and major depressive disorder (MDD). Research examining the use of rTMS for PTSD still remain limited, the majority of findings pertain to rTMS in MDD cohorts, which excluded individuals with PTSD. Given the high rate of PTSD with MDD comorbidity, additional studies examining this comorbid population are necessary.

Furthermore, rTMS treatment parameters and duration are rather time consuming for patients, requiring that patient travel to an outpatient facility daily, for 6 to 8 weeks, for 30 to 40 minutes each day. This can be an inconvenience and poses an additional burden for individuals that already struggle with societal integration and social/occupational dysfunction. Thus, further exploration and development of non-invasive brain stimulatory devices with the same (or better) effectiveness as rTMS, that can be adapted to be utilized in an at home setting, would revolutionize the treatment of PTSD.

The synchronized transcranial magnetic stimulation (sTMS, NeoSync Inc.) device provides the possibility of the fore mentioned therapeutic development. The sTMS device employs 3 transversely rotating, to deliver low energy, sinusoidal magnetic fields synchronized to an individuals' intrinsic alpha frequency (IAF). Preliminary data has shown that sTMS can effectively reduce depressive symptoms in MDD. Additionally, the investigators' preliminary examination of IAF in participants with comorbid PTSD and depressive symptoms, has illuminated the feasibility of this modality as a treatment approach for PTSD comorbid with MDD.

This study is a prospective, sham-controlled, trial of sTMS delivered to patients who are symptomatic despite ongoing pharmacotherapy for PTSD and mood symptoms. Eligible subjects will be randomized using to receive 4 weeks (5 daily sessions per week) of either sham or active sTMS treatment. Clinical and self-report assessments will be completed at baseline, sham/control series endpoint, and 1 month after the final treatment session. An optional open-label continuation phase will be offered to all study participants who complete the sham-control phase of this study, and additional endpoint assessments will be administered.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: October 26, 2018
• Est. primary completion date: October 26, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Must be a Veteran;

• MRI safe;

• Meet Diagnostic and Statistical Manual, Fifth Edition (DSM 5) criterion for PTSD (acute or chronic, confirmed by the Clinician Administered PTSD Scale (CAPS) and at least moderate severity defined by a PCL-5 score > 33); AND at least moderate depressive symptom severity (defined by QIDS-SR score > or equal to 11) at baseline visit. Individuals with bipolar II or otherwise unspecified who are currently in a depressed episode are eligible;

• Baseline score of "moderately ill" or worse on the Clinical Global Impressions-Severity (CGI-S);

• Stable psychotropic regimen for at least 6 weeks prior to baseline and willing to maintain current dose and regimen throughout study, or no psychotropic medication at all;

• If female and of child bearing potential, must agree to use an acceptable method of birth control for the duration of the study treatment period;

• Be willing and able to comply with all study related procedures and visits;

• Be capable of independently reading and understanding all patient information materials and giving written informed consent.

Exclusion Criteria:

• Pregnant or lactating, or planning on becoming pregnant within the next 3 months;

• Lifetime history of loss of consciousness (>10 minutes) due to head injury, or lifetime history of head injury with documented evidence of brain injury;

• Current (or past) significant neurological disorders (seizure disorder, primary or secondary central nervous system (CNS) tumors, stroke, cerebral aneurysm);

• Unstable medical illness, or significant absence of appropriate medical care;

• Current axis I primary psychotic disorder or Bipolar I disorder;

• Active (within the last month) moderate or severe substance (excluding nicotine/caffeine) abuse disorders. Individuals on stable (>3 months), monitored opiate agonist therapy may be included at investigator's discretion;

• Past failed treatment with rTMS or electroconvulsive therapy (ECT); any past treatment with deep brain stimulation or vagus nerve stimulation;

• Have an active suicidal intent or plan, or in the opinion of the investigator, is likely to attempt suicide in the next 6 months;

• Presence of condition or circumstance with potential to prevent study completion;

• Inability to obtain sufficient EEG to calibrate study device.

Related Conditions & MeSH terms

• Depression
• PTSD

Intervention

Device:
• NEST-1
The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.
• SHAM
The SHAM NeoSync EEG Synchronized TMS (NEST) is a device, identical to the active NEST-1 device, that is configured to simulate the delivery of active treatment without actively delivering sTMS therapy. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be SHAM compatible.
• NEST-2
The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.

Locations

Country	Name	City	State
United States	Providence VAMC	Providence	Rhode Island
United States	White River Junction VAMC	White River Junction	Vermont

Sponsors (2)

Lead Sponsor	Collaborator
Providence VA Medical Center	NeoSync, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PCL-5 Total Score Change	The PTSD checklist (PCL-5) will be used to assess PTSD symptom severity pre- and post-treatment. The change in total PCL-5 score from Baseline (Day 0) to endpoint (PT1) compared between active treatment and sham-controlled groups. If a participant does not complete PT1, last observation carried forward (LOCF) will be used. A 50% reduction in scores from Baseline scores to PT1 indicates clinical response to treatment (active sTMS vs. sham), and remission is defined by a post-treatment score below the threshold score published for the PCL-5.	Through Study Completion (up to 2 years)
Secondary	QIDS-SR Total Score Change: Clinical Response	The Quick Inventory of Depressive Symptoms-Self Report (QIDS-SR) is a 16 question self-rating assessment of depressive symptom severity. Pre- and post-treatment scores on the QIDS-SR will be analyzed and reported in a descriptive manner for the sample. Categorical response (empirically defined as 50% decrease from pre-treatment baseline) and remission (below threshold score, per published standards for each scale) at endpoint will be calculated and reported.	Through Study Completion (up to 2 years)
Secondary	Relationship between Intrinsic Alpha Frequency (IAF) and treatment outcomes	TMS will be synchronized to the Individual Alpha Frequency (IAF) of each participant, calculated using electroencephalography (EEG) prior to the first treatment. The relationship between mean IAF at baseline and treatment outcomes (i.e., change in total symptom severity) will be analyzed and reported for both groups, at PT1 and open-label continuation endpoint (OL PT1).	Through Study Completion (up to 2 years)
Secondary	Number of Participants with Adverse Event or Unexpected Side Effects: Safety Endpoint	Unexpected side effects and adverse events will be descriptively reported to analyze sTMS safety efficacy. The investigators will follow Institutional Review Board (IRB) guidelines for reporting significant and unexpected adverse events.	2 years